BOI.PA - Boiron SA

Boiron SA

2, avenue de l'Ouest Lyonnais
Messimy 69510
France
33 4 78 45 61 00
http://www.boiron.com

Sector: Healthcare
Industry: Drug Manufacturers - Major
Full-time employees: 3,084

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Valérie Lorentz-Poinsot	Gen. Mang. & Exec. Director	2.44M	N/A	1969
Mr. Bruno Grange	International Controller & Director	16.22k	N/A	1953
Mr. Jean-Christophe Bayssat	Deputy GM, Chief Pharmacist & Director of Pharmaceutical Devel.	1.18M	N/A	1963
Mr. Christian Boiron	Director	2.75M	N/A	1948
Fabrice Rey	Group Treasurer	N/A	N/A	N/A

Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum for the treatment of influenza symptoms; Stodal and Stodaline to treat coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for nursing babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's branded homeopathic medicines comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat ocular discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. It offers its products through distribution centers, pharmacy chains, wholesalers, supermarkets, drugstores, and health food stores. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Corporate governance

Boiron SA’s ISS governance QualityScore as of 29 July 2019 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.